author-photo

Linda Vocila

Translational Genomics Research Institute

16

Papers

161

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Author response for "Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial"

2021
Show All
- Source
- Cite
- Save
Citations (0)
Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.

2021 Molecular Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 3129: PD-L1 expression differs across cancer metastatic sites from breast tumors

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract P1-07-09: A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Enrichment of PI3K-AKT–mTOR pathway activation in hepatic metastases from breast cancer

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (47)
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Abstract P2-05-21: The AKT-mTOR pathway as a potential organ-specific drug target signature of hepatic metastases from breast cancer

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2043: Protein pathway activation mapping analysis of metastatic breast cancer reveals potential new targets for personalized therapy.

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

2012 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (50)